nt-0796
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 10, 2023 (NCT06129409)
Timeline
Indications
Mechanism of action
NLRP3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)OC(=O)[C@@H](Cc1ncccn1)OC(=O)Nc1c2c(cc3c1CCC3)CCC2- Mol. weight
- 409.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5409389 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07220629 | Phase 2 | Oct 2, 2025 | NodThera |
| NCT07055516 | Phase 2 | May 8, 2025 | NodThera |
| NCT06129409 | Phase 1/Phase 2 (Phase 2) | Oct 10, 2023 | NodThera |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NodThera | For profit | 3 | 3 | 1 | 2023 |
1 organizations
Page 1 / 1